Cancer Therapy Advisor interviewed Dr Bakal about this new approach to analyzing cell shape and its potential to affect breast cancer treatment.
Physicians will speak about tumor evolution and AR-indifferent disease at the 2017 ASCO Genitourinary Cancers Symposium in Orlando, Florida.
At a general session at the 2017 ASCO GU Symposium, the latest advances in managing SRMs will be discussed.
At an education session at the 2017 GU Symposium experts will discuss some of the barriers to progress in the treatment of bladder cancer.
The cost of treating CML can be crippling, and it's unclear whether future approvals or policies will improve the financial toxicity associated with the disease.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immunotherapy and the Future of Prostate Cancer Treatment
- Explaining Androgen Receptor-indifferent Prostate Cancer
- Dual Immunotherapy Active vs Sunitinib for PD-L1+ Advanced RCC
- 2017 ASCO GU Symposium: Updates in Managing Small Renal Masses
- First-line Immune Checkpoint Inhibition Cost-effective in Melanoma